Jan H von der Thusen
Overview
Explore the profile of Jan H von der Thusen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Schoonvelde S, Ruijmbeek C, Hirsch A, van Slegtenhorst M, Wessels M, von der Thusen J, et al.
Heart Rhythm
. 2023 Aug;
20(11):1512-1521.
PMID: 37562486
Background: Dilated cardiomyopathy (DCM) can be caused by truncating variants in the filamin C gene (FLNC). A new pathogenic FLNC variant, c.6864_6867dup, p.(Val2290Argfs∗23), was recently identified in Dutch patients with...
22.
Hondelink L, Ernst S, Atmodimedjo P, Cohen D, Wolf J, Dingemans A, et al.
Eur J Cancer
. 2023 Jan;
181:53-61.
PMID: 36638752
Objectives: The landmark ADAURA study recently demonstrated a significant disease-free survival benefit of adjuvant osimertinib in patients with resected EGFR-mutated lung adenocarcinoma. However, data on prevalence rates and stage distribution...
23.
van Kooten J, de Gooijer C, von der Thusen J, Brandt-Kerkhof A, Albers A, Lahaye M, et al.
Eur J Surg Oncol
. 2023 Jan;
49(3):611-618.
PMID: 36610896
Background: Malignant peritoneal mesothelioma (MPM) is a rare and aggressive cancer that has a poor prognosis. An earlier population-based study found that the majority of Dutch patients do not receive...
24.
Ernst S, Mankor J, van Riet J, von der Thusen J, Dubbink H, Aerts J, et al.
J Thorac Oncol
. 2022 Dec;
18(4):487-498.
PMID: 36528243
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing...
25.
Moonen L, Derks J, Lap L, Marijnissen B, Hillen L, den Bakker M, et al.
Transl Lung Cancer Res
. 2022 Dec;
11(11):2181-2191.
PMID: 36519022
Background: Orthopedia homeobox (OTP) has shown to be a useful prognostic marker to predict outcome in pulmonary carcinoids, which is also supported by the World Health Organization. However, the discontinuation...
26.
Shamier M, Crijnen Y, Bogers S, IJpelaar J, de Vries J, van der Jagt M, et al.
J Neuroimmunol
. 2022 Dec;
374:578007.
PMID: 36481703
Here, we describe the clinical phenotype of SARS-CoV-2-related CNS disease and evaluate the SARS-CoV-2 antibody index as a tool to differentiate between a direct (viral) and indirect etiology. Out of...
27.
Wismans L, Lopuhaa B, de Koning W, Moeniralam H, van Oosterhout M, Ambarus C, et al.
Histopathology
. 2022 Nov;
82(3):407-419.
PMID: 36366933
Aims: Lung tissue from COVID-19 patients shares similar histomorphological features with chronic lung allograft disease, also suggesting activation of autoimmune-related pathways in COVID-19. To more clearly understand the underlying spectrum...
28.
Huyuk M, Fiocco M, Postmus P, Cohen D, von der Thusen J
Histopathology
. 2022 Oct;
82(5):650-663.
PMID: 36282087
Lymph node micrometastases could be one of the reasons for the high recurrence rate after complete surgical resection in stage I-IIIA non-small cell lung cancer (NSCLC). The standard evaluation of...
29.
Dymek B, Sklepkiewicz P, Mlacki M, Guner N, Nejman-Gryz P, Drzewicka K, et al.
J Inflamm Res
. 2022 Oct;
15:5621-5634.
PMID: 36199746
Introduction: Sarcoidosis is a systemic disease of unknown etiology characterized by granuloma formation in the affected tissues. The pathologically activated macrophages are causatively implicated in disease pathogenesis and play important...
30.
Pruis M, Groenendijk F, Badloe K, van Puffelen A, Robbrecht D, Dinjens W, et al.
Br J Cancer
. 2022 May;
127(4):776-783.
PMID: 35606463
Background: Biomarker-guided therapy in an experimental setting has been suggested to improve patient outcomes. However, trial-specific pre-screening tests are time and tissue consuming and complicate the personalised treatment of patients...